Safety of TV-46000, long-acting injection for schizophrenia, consistent in phase 3 study

Among patients with schizophrenia, TV-46000 had a favorable safety profile that was consistent with other formulations of risperidone and previous studies of TV-46000, according to a study published in CNS Drugs.
As Healio previously reported, the FDA approved TV-46000 (Uzedy; Teva Pharmaceuticals, MedinCell), a long-acting subcutaneous risperidone injection, in April 2023 for the treatment of schizophrenia in adults.
“The confirmatory research reinforces Uzedy as a safe and effective long-acting treatment option for people living with schizophrenia, including African Americans who,

Among patients with schizophrenia, TV-46000 had a favorable safety profile that was consistent with other formulations of risperidone and previous studies of TV-46000, according to a study published in CNS Drugs.
As Healio previously reported, the FDA approved TV-46000 (Uzedy; Teva Pharmaceuticals, MedinCell), a long-acting subcutaneous risperidone injection, in April 2023 for the treatment of schizophrenia in adults.
“The confirmatory research reinforces Uzedy as a safe and effective long-acting treatment option for people living with schizophrenia, including African Americans who,